The targeted protein to minimize the generation of Aβ42 is β-secretase 1 (BACE1), which is involved in the first proteolytic cleavage of the APP protein and also γ-secretase which plays a role in the second cleavage in order to produce the Aβ42 protein.Verubecestat, a BACE1 inhibitor, was discontinued from the phase III trial due to its lack of efficacy and inability to establish a positive risk/benefit ratio towards mild-to-moderate and prodromal AD patients, although significant reduction of Aβ in the patients' CSF and brains were achieved during the trial (Egan et al., 2018). The gene discussed is APP; the disease is Alzheimer disease.